1. ea al. Growth hormone release inhibiting hormone in acromegaly;Besser, G.M.; Mortimer, C.H.; Carr, D.; Schally, A.X.T.; Coy, D.H.; Evered, D.;BAIJ,1974
2. Somatostatin and its physiology in health and disease. In: Clinical neuroendocrinology;Wass, J.A.H.,1982
3. Long-term treatment of acromegalv with the somatostatin analogue SMS 201-995;Lamberts, S.W.J.; Uitterlinden, P.; Verschoor, L.; Van Dongen, K.J.; Del Pozo, E.;N Engl 7 Med,1985
4. Somatostatinoma syndrome;Kreis, G.J.; Orci, L.; Conlon, M.; Ravazzola, M.; Davis, G.R.; Raskin, P.;N Engl j7 Med,1979
5. Assessment of gall bladder dynamics and the development of gall stones during octreotide therapy for acromegaly;Ewins, D.L.; Javaid, A.; Coskeran, P.; Deprez, P.M.; Barrett, J.J.; McGregor, A.M.;[Abstract.],1991